article thumbnail

Top 5 Articles for Retail Pharmacists in 2022

Pharmacy Times

This year, retail pharmacists were interested in diabetes research, saving patients money, and influenza vaccine candidates.

Vaccines 148
article thumbnail

Alzheimer’s vaccine granted Fast Track designation

European Pharmaceutical Review

AC Immune SA has received Fast Track designation from the US Food and Drug Administration (FDA) for its anti-amyloid beta (Abeta) active immunotherapy vaccine candidate for Alzheimer’s disease. The anti-Abeta therapy “specifically targets the most toxic forms of Abeta” according to Dr Andrea Pfeifer, CEO of AC Immune SA.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Meeting Global Demands for Viral Vector-based Vaccines

Pharma Mirror

In the face of increasing global health challenges, the development and production of vaccines have become paramount. One critical aspect is the ability to scale up manufacturing processes to meet the growing demand for viral vector-based vaccines.

article thumbnail

Advances in Plant-Made Vaccine Technology

Pharmaceutical Commerce

Review article explores the latest developments surrounding expression and purification strategies.

Vaccines 105
article thumbnail

Could personalised mRNA vaccine be first for cancer?

European Pharmaceutical Review

A BioNTech-led Phase I trial demonstrated preliminary evidence that adjuvant autogene cevumeran, a personalised mRNA neoantigen vaccine, in combination with atezolizumab (Genentech) and mFOLFIRINOX can induce substantial T cell activity in pancreatic ductal adenocarcinoma (PDAC). Can an mRNA vaccine stimulate T cell response?

article thumbnail

JCVI backs RSV routine vaccination for babies and older adults in the UK

Hospital Pharmacy Europe

The UK should introduce routine vaccination for respiratory syncytial virus (RSV) to protect babies and older adults, the Joint Committee on Vaccination and Immunisation (JCVI) has recommended. This article was originally published by our sister title Pulse.

article thumbnail

Combined flu and Covid vaccine sees strong early trial results, says Moderna

Hospital Pharmacy Europe

Moderna has announced its combined flu and Covid vaccine has generated strong immunogenicity in early-stage trials. Interim results from its phase 1/2 studies found the vaccine (mRNA-1083) generated antibody levels similar to or greater than flu vaccines as well as similar results to the standalone Moderna Covid jab.